As India’s Diabetes Market Grows, Eli Lilly Brings In A New Leader
This article was originally published in PharmAsia News
With an eye on diabetes and non-communicable diseases, Lilly taps new leadership in India.
You may also be interested in...
MUMBAI - Explosive growth in India's anti-diabetes medicines market is turning arch rivals into allies. The latest example is of Eli Lilly & Co. combining forces with German giant Boehringer Ingelheim GmbH.
MUMBAI - Following the Indian government's heightened concerns over a sharply increased prevalence rate of non-communicable diseases such as diabetes and cancer, Eli Lilly & Co. has allocated $8-9 million to analyze the disease burden in India and devise intervention strategies based on the data
MUMBAI - Alarmed by the rapid increase in the number of non-communicable diseases, India's ministry of health and family welfare announced that the recently unveiled National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke will be extended to the entire country over the next five years